In ALL, MDM2 overexpression is frequently observed [73,74,75], especially in T-ALL where cyclin-dependent kinase Inhibitor 2A (CDKN2A) disrupts p14, a negative regulator of MDM2 expression [76]. Here, MDM2 is linked to acute lymphoblastic leukemia.